866-997-4948(US-Canada Toll Free)

Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market

Published By :

GBI Research

Published Date : Feb 2011

Category :

Prescription Drugs

No. of Pages : 195 Pages


GBI Research, the leading business intelligence provider, has released its latest research, Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market, which provides insights into global antibacterial market and market forecast until 2016. 

The report provides an in-depth analysis of the top seven therapeutic indications for which often antibacterials are prescribed which includes tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media. The report also examines the Global antibacterial treatment usage patterns for the covered indication. In addition, the report also includes insights into the antibacterial R&D pipeline. 

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Research analysis shows that the overall global antibacterial market for the seven indications tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media is valued at $11,070m in 2009. The market is expected to witness a growth at a CAGR of 1.5% for the forecast period and will reach $12,160m by 2016. 

Patent expiries of leading antbacterial, weak pipelines, increase in prevalence and prescription populations and easy availability of generic products are the main reason for growth in antbacterial market. The top pharmaceutical companies in antibacterial market companies Pfizer, Sanofi-Aventis, Abbott, Bayer HealthCareAG, Johnson & Johnson, Daiichi-Sankyo and Teva pharmaceuticals. Large amount of fragmentation in the market provides significant scope for consolidation through mergers and acquisitions. 

Scope

The scope of this report includes -

  • Data and analysis on the global antibacterial market.
  • Annualized market data for the antibacterial market from 2001 to 2009, with forecasts to 2016.
  • Market data on the therapeutic landscape which covers tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
  • Key drivers and restraints that have had a significant impact on the market and on each indication.
  • The competitive landscape of the global anticonvulsant market which includes companies such as Pfizer, Sanofi-Aventis, Abbott, Bayer HealthCare AG, Johnson & Johnson, Daiichi-Sankyo and Teva.
  • Key M&A activities and Licensing Agreements that took place from 2005 to 2010 in the global antibacterial market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Device a more tailored country strategy through the understanding of key drivers and barriers of the regions antibacterial market.
  • Develop key strategic initiatives by understanding the key focus areas and top selling antibacterial molecules of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents

1 Table of Contents 3

1.1 List of Tables 8
1.2 List of Figures 11

2 Anti-Bacterials Market to 2016 Introduction 15
2.1 GBI Research Report Guidance 15

3 Anti-Bacterials Market to 2016 Overview 16
3.1 Bacterial Classification 16
3.1.1 Antimicrobial Spectrum 16
3.1.2 Bacterial Resistance 16
3.1.3 Cephalosporin Antibiotic 16
3.1.4 Penicillin Antibiotic 18
3.1.5 Quinolones Antibiotic 20
3.1.6 Macrolide Antibiotic 20
3.2 Antibacterials Market Size 21
3.2.1 Antibacterial Market Size by Geography 22
3.2.2 Antibacterial Market Size by indication 23
3.3 Drivers and Barriers for the Antibacterial Market 24
3.3.1 Drivers for Antibacterial Market 24
3.3.2 Barriers for Antibacterial Market 25

4 Anti-Bacterials Market to 2016 Tuberculosis 26
4.1 Overview 26
4.1.1 Microbiology 26
4.1.2 Diagnosis 26
4.1.3 Treatment 26
4.1.4 Prevention 27
4.2 Tuberculosis Drugs Market Size 27
4.3 Tuberculosis Drugs Market Forecast and CAGR 28
4.4 Drivers and Barriers for Tuberculosis Therapeutics Market 33
4.4.1 Drivers for the Tuberculosis Drugs Market 33
4.4.2 Barriers to Tuberculosis Drugs 34
4.5 Product Profile of the Major Marketed Products in the Tuberculosis Market 34
4.5.1 Isoniazid (INH) 34
4.5.2 Rifampin (RIF) 35
4.5.3 Pyrazinamide (PZA) 35
4.5.4 Ethambutol (EMB) 36
4.5.5 Kanamycin 36
4.5.6 Ofloxacin 36
4.5.7 Ethionamide 37
4.6 Global Tuberculosis Market: Pipeline Analysis 37
4.6.1 Overview 37
4.6.2 Research and Development Pipeline- Discovery 38
4.6.3 Research and Development Pipeline Preclinical 38
4.6.4 Research and Development Pipeline - Phase I 42
4.6.5 Research and Development Pipeline - Phase II 43
4.6.6 Research and Development Pipeline - Phase III 48
4.7 Global Tuberculosis Market: Strategic Consolidations 52
4.7.1 Overview 52
4.7.2 Merger and Acquisition Deals 52
4.7.3 Research and Development Licensing Agreements 55
4.7.4 Co-Developments 56

5 Anti-Bacterials Market to 2016 Pneumonia 58
5.1 Overview 58
5.1.1 Microbiology 58
5.1.2 Diagnosis 58
5.1.3 Treatment 59
5.1.4 Prevention 60
5.2 Pneumonia Drugs Market Size 60
5.3 Pneumonia Drugs Market Forecast and CAGR 61
5.4 Drivers and Barriers to Pneumonia Therapeutics Market 70
5.4.1 Drivers to Pneumonia Drugs market 70
5.4.2 Barriers to Pneumonia Drugs market 71
5.5 Product Profile of the Major Marketed Products in the Pneumonia Market 71
5.5.1 Zyvox (linezolid) 71
5.5.2 Zosyn (piperacillin and tazobactum) 71
5.5.3 Levaquin (Levofloxacin) 72
5.5.4 Avelox (moxifloxacin) 72
5.5.5 Omnicef (cefnidir) 72
5.5.6 Tygacil (tigecycline) 72
5.5.7 Doribax (doripenem) 73
5.6 Global Pneumonia Therapeutics Market: Pipeline Assessment 73
5.6.1 Overview 73
5.6.2 Discovery 73
5.6.3 Pre-Clinical 74
5.6.4 Phase I 75
5.6.5 Phase II 76
5.6.6 Phase III 77
5.7 Global Pneumonia Market: Strategic Consolidations 78
5.7.1 Overview 78
5.7.2 Merger and Acquisition Deals 79
5.7.3 Research and Development Licensing Agreements 82
5.7.4 Co-Developments 84

6 Anti-Bacterials Market to 2016 Urinary Tract Infection 86
6.1 Overview 86
6.1.1 Microbiology 86
6.1.2 Diagnosis 86
6.1.3 Treatment 87
6.1.4 Prevention 87
6.2 Urinary Tract Infection Market Size 87
6.3 Urinary Tract Infections Market Forecast and CAGR 87
6.4 Drivers and Barriers for the Urinary Tract Infection Therapeutics Market 96
6.4.1 Drivers for the UTI market 96
6.4.2 Barriers for the UTI Market 97
6.5 Product Profile of the Major Marketed Products in the Urinary Tract Infection Market 97
6.5.1 Doribax (Doripenem) 97
6.5.2 Ciprofloxacin 98
6.5.3 Levaquin (levafloxacin) 99
6.5.4 Monurol (fosfomycin tromethamine) 101
6.5.5 Macrobid (Nitrofurantoin) 102
6.5.6 Bactrim/Septra (trimethoprim/sulfamethoxazole) 102
6.6 Global Urinary Tract Infection Market: Pipeline Assessment 103
6.6.1 Overview 103
6.6.2 Discovery 104
6.6.3 Phase I 104
6.6.4 Phase II 105
6.6.5 Phase III 106
6.7 Global Urinary Tract Infection Therapeutics Market: Strategic Consolidations 106
6.7.1 Overview 106
6.7.2 Mergers and Acquisitions Deals 107
6.7.3 Research and Development Licensing Agreements 110
6.7.4 Co-Developments 112

7 Anti-Bacterials Market to 2016 Atypical Bronchitis 113
7.1 Overview 113
7.1.1 Microbiology 113
7.1.2 Diagnosis 113
7.1.3 Treatment 113
7.1.4 Prevention 113
7.2 Atypical Bronchitis Market Size 113
7.3 Atypical Bronchitis Market Forecast and CAGR 114
7.4 Drivers and Barriers for Atypical Bronchitis Therapeutics Market 123
7.4.1 Drivers for atypical Bronchitis 123
7.4.2 Barriers for Atypical Bronchitis 123
7.5 Global Atypical Bronchitis Therapeutics Market: Pipeline Assessment 124
7.5.1 Overview 124
7.5.2 Phase III 124
7.6 Global Atypical Bronchitis Therapeutics Market: Strategic Consolidations 124
7.6.1 Overview 124
7.6.2 Mergers and Acquisitions Deals 125
7.6.3 Research and Development Licensing Agreements 127
7.6.4 Co-Developments 129

8 Anti-Bacterials Market to 2016 Tonsillitis 130
8.1 Overview 130
8.1.1 Microbiology 130
8.1.2 Diagnosis 130
8.1.3 Treatment 130
8.1.4 Prevention 130
8.2 Tonsillitis Market Size 130
8.3 Tonsillitis Therapeutics Market Forecast and CAGR 131
8.4 Drivers and Barriers for Tonsillitis Therapeutics Market 140
8.4.1 Drivers for Tonsillitis 140
8.4.2 Barriers for Tonsillitis 140
8.5 Global Tonsillitis Market: Pipeline Assessment 140
8.5.1 Overview 140
8.5.2 Research and Development Pipeline - Phase II 140
8.6 Global Tonsillitis Market: Strategic Consolidations 141
8.6.1 Overview 141
8.6.2 Mergers and Acquisitions (M&A) Deals 141

9 Anti-Bacterials Market to 2016 Sinusitis 143
9.1 Overview 143
9.1.1 Microbiology 143
9.1.2 Diagnosis 143
9.1.3 Treatment 144
9.1.4 Prevention 144
9.2 Sinusitis Market Size 144
9.3 Sinusitis Therapeutics Market Forecast and CAGR 145
9.4 Drivers and Barriers for Sinusitis Therapeutics Market 154
9.4.1 Drivers for Sinusitis 154
9.4.2 Barriers for Sinusitis 154
9.5 Global Sinusitis Market: Pipeline Assessment 155
9.5.1 Overview 155
9.5.2 Pre-Clinical 155
9.5.3 Phase II 155
9.5.4 Phase III 156
9.6 Global Sinusitis Therapeutics Market: Strategic Consolidations 157
9.6.1 Overview 157
9.6.2 Mergers and Acquisitions Deals 157
9.6.3 Research and Development Licensing Agreements 159
9.6.4 Co-Developments 161

10 Anti-Bacterials Market to 2016 Otitis Media 162
10.1 Overview 162
10.1.1 Microbiology 162
10.1.2 Diagnosis 162
10.1.3 Treatment 162
10.1.4 Prevention 163
10.2 Ottis Media Market Size 163
10.3 Otitis Media Therapeutics Market Forecast and CAGR 163
10.4 Drivers and Barriers for Otitis Media Therapeutics Market 172
10.4.1 Drivers for Otitis Media 172
10.4.2 Barriers for Otitis Media 172
10.5 Global Ottis Media: Pipeline Assessment 173
10.5.1 Overview 173
10.5.2 Otitis Media Promising Drugs under Clinical development 173
10.6 Global Otitis Media Market: Strategic Consolidations 175
10.6.1 Overview 175
10.6.2 Mergers and Acquisitions Deals 175

11 Anti-Bacterials Market to 2016 Company Profiles 178
11.1 Pfizer 178
11.1.1 Overview 178
11.1.2 Financial Performance 178
11.1.3 Product Portfolio 178
11.1.4 SWOT Profile 179
11.2 Johnson & Johnson 179
11.2.1 Overview 180
11.2.2 Financial performance 180
11.2.3 Product portfolio 180
11.2.4 SWOT Profile 180
11.3 Daiichi-Sankyo 181
11.3.1 Overview 181
11.3.2 Financial Performance 181
11.3.3 Product Portfolio 181
11.3.4 SWOT Profile 182
11.4 Bayer HealthCare AG 182
11.4.1 Overview 183
11.4.2 Financial Performance 183
11.4.3 Product Portfolio 183
11.4.4 SWOT Profile 183
11.5 Sanofi-Aventis 184
11.5.1 Overview 184
11.5.2 Financial performance 184
11.5.3 Antibacterial Products 184
11.5.4 SWOT Profile 185
11.6 Abbott Laboratories 185
11.6.1 Overview 186
11.6.2 Financial Performance 186
11.6.3 Product Portfolio 186
11.6.4 SWOT Profile 186
11.7 Teva Pharmaceutical Industries Limited 187
11.7.1 Overview 187
11.7.2 Financial performance 187
11.7.3 Product Portfolio 187

12 Anti-Bacterial Market to 2016 Appendix 188
12.1 Market Definition 188
12.2 Abbreviations 188
12.3 Research Methodology 191
12.3.1 Coverage 191
12.3.2 Secondary Research 191
12.3.3 Primary Research 191
12.3.4 Forecasting 192
12.3.5 Expert Panels Validation 194
12.4 Contact Us 195
12.5 Disclaimer 195
12.6 Sources 195

List of Table


Table 1: Antibacterials Therapeutics Market, Classification, Cephalosporin Antibiotics by Generations, 2010 17
Table 2: Antibacterials Therapeutics Market, Penicillin Antibiotics by Classification, 2010 19
Table 3: Tuberculosis Therapeutics Market, Global, Revenue ($m), 2001-2009 28
Table 4: Tuberculosis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 29
Table 5: Tuberculosis Therapeutics Market, By Region, Revenue ($m), 2001-2009 30
Table 6: Tuberculosis Therapeutics Market, By Region, Revenue Forecasts ($m), 2009-2016 30
Table 7: Tuberculosis Therapeutics Market, Global, ACT ($m), 2001-2009 31
Table 8: Tuberculosis Therapeutics Market, Global, ACT ($m), 2009-2016 31
Table 9: Tuberculosis Therapeutics Market, Global, Prevalence Population (000), 2001-2009 32
Table 10: Tuberculosis Therapeutics Market, Global, Prevalence Population (000), 2009-2016 32
Table 11: Tuberculosis Therapeutics Market, Pipeline, Discovery Stage Molecules, 2010 38
Table 12: Tuberculosis Therapeutics Market, Global, M&A Deals by Value ($m), 2004-2010 54
Table 13: Tuberculosis Therapeutics Market, Global, Licensing Agreements by Value ($m), 2010 55
Table 14: Pneumonia Therapeutics Market, Global, Revenue ($m), 2001-2009 61
Table 15: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 62
Table 16: Pneumonia Therapeutics Market, By Region, Revenue ($m), 2001-2009 63
Table 17: Pneumonia Therapeutics Market, By Region, Revenue Forecasts ($m), 2009-2016 63
Table 18: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 64
Table 19: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 64
Table 20: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns (000), 2001-2009 65
Table 21: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns (000), 2009-2016 65
Table 22: Pneumonia Therapeutics Market, Global, Prevalence Population (000), 2001-2009 66
Table 23: Pneumonia Therapeutics Market, Global, Prevalence Population (000), 2009-2016 66
Table 24: Pneumonia Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2009 67
Table 25: Pneumonia Therapeutics Market, Global, Treatment Seeking Population (Million), 2009-2016 67
Table 26: Pneumonia Therapeutics Market, Global, Diagnosed Population (000), 2001-2009 68
Table 27: Pneumonia Therapeutics Market, Global, Diagnosed Population (000), 2009-2016 68
Table 28: Pneumonia Therapeutics Market, Global, Prescription Population (000), 2001-2009 69
Table 29: Pneumonia Therapeutics Market, Global, Prescription Population (000), 2009-2016 69
Table 30: Pneumonia Therapeutics Market, Global, M&A Deals by Value ($m), 2005-2010 80
Table 31: Pneumonia Therapeutic Market, Global, Licensing Agreements by Value ($m), 2004-2010 83
Table 32: Pneumonia Therapeutic Market, Global, Co-Developments by Value ($m), 2005-2010 85
Table 33: Urinary Tract Infection Therapeutics Market, Global, Revenue ($m), 2001-2009 87
Table 34: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 88
Table 35: Urinary Tract Infection Therapeutics Market, By Region, Revenue ($m), 2001-2009 89
Table 36: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 89
Table 37: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 90
Table 38: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 90
Table 39: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2009 91
Table 40: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Patterns (Million), 2009-2016 91
Table 41: Urinary Tract Infection Therapeutics Market, Global, Prevalence Population (Million), 2001-2009 92
Table 42: Urinary Tract Infection Therapeutics Market, Global, Prevalence Population (Million), 2009-2016 92
Table 43: Urinary Tract Infection Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2009 93
Table 44: Urinary Tract Infection Therapeutics Market, Global, Treatment Seeking Population (Million), 2009-2016 93
Table 45: Urinary Tract Infection Therapeutics Market, Global, Diagnosed Population (Million), 2001-2009 94
Table 46: Urinary Tract Infection Therapeutics Market, Global, Diagnosed Population (Million), 2009-2016 94
Table 47: Urinary Tract Infection Therapeutics Market, Global, Prescription Population (Million), 2001-2009 95
Table 48: Urinary Tract Infection Therapeutics Market, Global, Prescription Population (Million), 2009-2016 95
Table 49: Urinary Tract Infection Therapeutics Market, Pipeline, Discovery Stage Molecules, 2010 104
Table 50: Urinary Tract Infection Therapeutics Market, Pipeline, Phase II Molecules, 2010 105
Table 51: Urinary Tract Infection Therapeutics Market, Pipeline, Phase III Molecules, 2010 106
Table 52: Urinary Tract Infection Therapeutics Market, Global, M&A Deals by Value ($m), 2004-2010 108
Table 53: Urinary Tract Infection Therapeutics Market, Global, Licensing Agreements by Value ($m), 2005-2010 111
Table 54: Atypical Bronchitis Therapeutics Market, Global, Revenue ($m), 2001-2009 114
Table 55: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 115
Table 56: Atypical Bronchitis Therapeutics Market, By Region, Revenue ($m), 2001-2009 116
Table 57: Atypical Bronchitis Therapeutics Market, By Region, Revenue Forecasts ($m), 2009-2016 116
Table 58: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 117
Table 59: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 117
Table 60: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (000), 2001-2009 118
Table 61: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (000), 2009-2016 118
Table 62: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Prevalence Population (Million), 2001-2009 119
Table 63: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Prevalence Population (Million), 2009-2016 119
Table 64: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Treatment Seeking Population (Million), 2001-2009 120
Table 65: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Treatment Seeking Population (Million), 2009-2016 120
Table 66: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Diagnosed Population (000), 2001-2009 121
Table 67: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Diagnosed Population (000), 2009-2016 121
Table 68: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Prescription Population (000), 2001-2009 122
Table 69: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Prescription Population (000), 2009-2016 122
Table 70: Atypical Bronchitis Therapeutics Market, Global, M&A Deals by Value ($m), 2009-2010 125
Table 71: Tonsillitis Therapeutics Market, Global, Revenues ($m), 2001-2009 131
Table 72: Tonsillitis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 132
Table 73: Tonsillitis Therapeutics Market, By Region, Revenue ($m), 2001-2009 133
Table 74: Tonsillitis Therapeutics Market, By Region, Revenue Forecasts ($m), 2009-2016 133
Table 75: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 134
Table 76: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 134
Table 77: Tonsillitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2009 135
Table 78: Tonsillitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2009-2016 135
Table 79: Tonsillitis Therapeutics Market, Global, Prevalence Population (Million), 2001-2009 136
Table 80: Tonsillitis Therapeutics Market, Global, Prevalence Population (Million), 2009-2016 136
Table 81: Tonsillitis Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2009 137
Table 82: Tonsillitis Therapeutics Market, Global, Treatment Seeking Population (Million), 2009-2016 137
Table 83: Tonsillitis Therapeutics Market, Global, Diagnosed Population (Million), 2001-2009 138
Table 84: Tonsillitis Therapeutics Market, Global, Diagnosed Population (Million), 2009-2016 138
Table 85: Tonsillitis Therapeutics Market, Global, Prescription Population (Million), 2001-2009 139
Table 86: Tonsillitis Therapeutics Market, Global, Prescription Population (Million), 2009-2016 139
Table 87: Tonsillitis Therapeutics Market, Global, M&A Deals by Value ($m), 2006-2010 141
Table 88: Sinusitis Therapeutics Market, Global, Revenues ($bn), 2001-2009 145
Table 89: Sinusitis Therapeutics Market, Global, Revenues Forecasts ($bn), 2009-2016 146
Table 90: Sinusitis Therapeutics Market, By Region, Revenues ($m), 2001-2009 147
Table 91: Sinusitis Therapeutics Market, By Region, Revenues Forecasts ($m), 2009-2016 147
Table 92: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 148
Table 93: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 148
Table 94: Sinusitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2009 149
Table 95: Sinusitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2009-2016 149
Table 96: Sinusitis Therapeutics Market, Global, Prevalence Population (Million), 2001-2009 150
Table 97: Sinusitis Therapeutics Market, Global, Prevalence Population (Million), 2009-2016 150
Table 98: Sinusitis Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2009 151
Table 99: Sinusitis Therapeutics Market, Global, Treatment Seeking Population (Million), 2009-2016 151
Table 100: Sinusitis Therapeutics Market, Global, Diagnosed Population (Million), 2001-2009 152
Table 101: Sinusitis Therapeutics Market, Global, Diagnosed Population (Million), 2009-2016 152
Table 102: Sinusitis Therapeutics Market, Global, Prescription Population (Million), 2001-2009 153
Table 103: Sinusitis Therapeutics Market, Global, Prescription Population (Million), 2009-2016 153
Table 104: Sinusitis Therapeutics Market, Global, M&A Deals By Value ($m), 2004-2010 158
Table 105: Sinusitis Therapeutics Market, Global, Licensing Agreements By Value ($m), 2004-2010 160
Table 106: Otitis Media Therapeutics Market, Global, Revenues ($m), 2001-2009 163
Table 107: Otitis Media Therapeutics Market, Global, Revenues Forecasts ($m), 2009-2016 164
Table 108: Otitis Media Therapeutics Market, By Region, Revenues ($m), 2001-2009 165
Table 109: Otitis Media Therapeutics Market, By Region, Revenues Forecasts ($m), 2009-2016 165
Table 110: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 166
Table 111: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 166
Table 112: Otitis Media Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2009 167
Table 113: Otitis Media Therapeutics Market, Global, Treatment Usage Patterns (Million), 2009-2016 167
Table 114: Otitis Media Therapeutics Market, Global, Prevalence Population (Million), 2001-2009 168
Table 115: Otitis Media Therapeutics Market, Global, Prevalence Population (Million), 2009-2016 168
Table 116: Otitis Media Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2009 169
Table 117: Otitis Media Therapeutics Market, Global, Treatment Seeking Population (Million), 2009-2016 169
Table 118: Otitis Media Therapeutics Market, Global, Diagnosed Population (Million), 2001-2009 170
Table 119: Otitis Media Therapeutics Market, Global, Diagnosed Population (Million), 2009-2016 170
Table 120: Otitis Media Therapeutics Market, Global, Prescription Population (Million), 2001-2009 171
Table 121: Otitis Media Therapeutics Market, Global, Prescription Population (Million), 2009-2016 171
Table 122: Otitis Media Therapeutics Market, Pipeline, Preclinical Stage Molecules, 2010 173
Table 123: Otitis Media Therapeutics Market, Pipeline, Phase II Molecules, 2010 173
Table 124: Otitis Media Therapeutics Market, Pipeline, Phase III Molecules, 2010 174
Table 125: Otitis Media Therapeutics Market, Global, M&A Deals, 2009-2010 177

List of Chart


Figure 1: Antibacterials Therapeutics Market, Global, Revenues Forecasts ($m), 20012016 20
Figure 2: Antibacterials Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016 21
Figure 3: Antibacterials Therapeutics Market, Global, Revenue Share by Indication (%), 2009 22
Figure 4: Antibacterials Therapeutics Market, Drivers and Barriers, 2009-2016 23
Figure 5: Tuberculosis Therapeutics Market, Drugs Used In The Treatment of Tuberculosis, 2010 26
Figure 6: Tuberculosis Therapeutics Market, Global, Revenue ($m), 2001-2009 27
Figure 7: Tuberculosis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 28
Figure 8: Tuberculosis Therapeutics Market, By Region, Revenue Forecasts ($m), 2001-2016 29
Figure 9: Tuberculosis Therapeutics Market, Revenue Share by Geography (%), 2009 30
Figure 10: Tuberculosis Therapeutics Market, Global, ACT ($m), 2001-2016 30
Figure 11: Tuberculosis Therapeutics Market, Global, Prevalence Population (000), 2001-2016 31
Figure 12: Tuberculosis Therapeutic Market, Market Drivers and Barriers, 2009-2016 32
Figure 13: Tuberculosis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 36
Figure 14: Tuberculosis Therapeutics Market, Global, Strategic Consolidations (%), 2004-2010 51
Figure 15: Tuberculosis Therapeutics Market, Global, M&A Deals By Geography (%), 2004-2010 51
Figure 16: Tuberculosis Therapeutics Market, Global, M&A Deals By Deal Type (%), 2004-2010 52
Figure 17: Tuberculosis Therapeutics Market, Global, M&A Deals By Year, 2004-2010 52
Figure 18: Tuberculosis Therapeutics Market, Global, Licensing Agreements by Geography (%), 2004-2010 54
Figure 19: Tuberculosis Therapeutics Market, Global, Licensing Agreements by Year, 2004-2010 55
Figure 20: Tuberculosis Therapeutics Market, Global, Co-Developments by Geography (%), 2004-2010 55
Figure 21: Tuberculosis Therapeutics Market, Global, Co-Developments by Year, 2004-2010 56
Figure 22: Pneumonia Therapeutics Market, Drugs used in the Treatment of Pneumonia, 2010 58
Figure 23: Pneumonia Therapeutics Market, Global, Revenue ($m), 2001-2009 60
Figure 24: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 61
Figure 25: Pneumonia Therapeutics Market, By Region, Revenue Forecasts ($m), 2001-2016 62
Figure 26: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 63
Figure 27: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns (000), 2001-2016 64
Figure 28: Pneumonia Therapeutics Market, Global, Prevalence Population (000), 2001-2016 65
Figure 29: Pneumonia Therapeutics Market, Global, Treatment Seeking Population (000), 2001-2016 66
Figure 30: Pneumonia Therapeutics Market, Global, Diagnosed Population (000), 2001-2016 67
Figure 31: Pneumonia Therapeutics Market, Global, Prescription Population (000), 2001-2016 68
Figure 32: Pneumonia Therapeutics Market, Global, Market Drivers and Barriers, 2009-2016 69
Figure 33: Pneumonia Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 72
Figure 34: Pneumonia Therapeutics Market, Global, Strategic Consolidations (%), 2004-2010 77
Figure 35: Pneumonia Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2010 78
Figure 36: Pneumonia Therapeutics Market, Global, M&A Deals by Deal Type (%), 2004-2010 80
Figure 37: Pneumonia Therapeutics Market, Global, M&A Deals by Year, 2004-2010 80
Figure 38: Pneumonia Therapeutics Market, Global, Licensing Agreements by Geography (%), 2004-2010 81
Figure 39: Pneumonia Therapeutics Market, Global, Licensing Agreements by Year, 2004-2010 83
Figure 40: Pneumonia Therapeutics Market, Global, Co-Developments by Geography (%), 2005-2010 83
Figure 41: Pneumonia Therapeutic Market, Global, Co-Developments by Year, 2005-2010 84
Figure 42: Urinary Tract Infection Therapeutics Market, Global, Revenue ($m), 2001-2009 86
Figure 43: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 87
Figure 44: Urinary Tract Infection Therapeutics Market, By Region, Revenue Forecasts ($m), 2001-2016 88
Figure 45: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 89
Figure 46: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2016 90
Figure 47: Urinary Tract Infection Therapeutics Market, Global, Prevalence Population (Million), 2001-2016 91
Figure 48: Urinary Tract Infection Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2016 92
Figure 49: Urinary Tract Infection Therapeutics Market, Global, Diagnosed Population (Million), 2001-2016 93
Figure 50: Urinary Tract Infection Therapeutics Market, Global, Prescription Population (Million), 2001-2016 94
Figure 51: Urinary Tract Infection Therapeutics Market, Global, Market Drivers and Barriers, 2009-2016 95
Figure 52: Urinary Tract Infection Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 102
Figure 53: Urinary Tract Infection Therapeutics Market, Global, Strategic Consolidations (%), 2004-2010 105
Figure 54: Urinary Tract Infection Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2010 106
Figure 55: Urinary Tract Infection Therapeutics Market, Global, M&A Deals by Deal Type (%), 2004-2010 108
Figure 56: Urinary Tract Infection Therapeutics Market, Global, M&A Deals by Year, 2004-2010 109
Figure 57: Urinary Tract Infection Therapeutics Market, Global, Licensing Agreements by Geography (%), 2005-2010 109
Figure 58: Urinary Tract Infection Therapeutics Market, Global, Licensing Agreements by Year, 2005-2010 110
Figure 59: Urinary Tract Infection Therapeutics Market, Global, Licensing Agreements by Organizations (%), 2005-2010 111
Figure 60: Atypical Bronchitis Therapeutics Market, Global, Revenue ($m), 2001-2009 113
Figure 61: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 114
Figure 62: Atypical Bronchitis Therapeutics Market, By Region, Revenue Forecasts ($m), 2001-2016 115
Figure 63: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 116
Figure 64: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (000), 2001-2016 117
Figure 65: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Prevalence Population (Million), 2001-2016 118
Figure 66: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Treatment Seeking Population (Million), 2001-2016 119
Figure 67: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Diagnosed Population (000), 2001-2016 120
Figure 68: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Prescription Population (000), 2001-2016 121
Figure 69: Atypical Bronchitis Therapeutics Market, Market Drivers and Barriers, 2009-2016 122
Figure 70: Atypical Bronchitis Infection Therapeutics Market, Global, Strategic Consolidations (%), 2004-2010 123
Figure 71: Atypical Bronchitis Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2010 124
Figure 72: Atypical Bronchitis Therapeutics Market, Global, M&A Deals by Deal Type (%), 2004-2010 125
Figure 73: Atypical Bronchitis Therapeutics Market, Global, M&A Deals by Year, 2004-2010 125
Figure 74: Atypical Bronchitis Therapeutics Market, Global, Licensing Agreements by Geography (%), 2005-2010 126
Figure 75: Atypical Bronchitis Therapeutics Market, Global, Licensing Agreements by Year, 2005-2010 127
Figure 76: Atypical Bronchitis Therapeutics Market, Global, Licensing Agreements by Organizations (%), 2005-2010 127
Figure 77: Atypical Bronchitis Therapeutics Market, Global, Co-Developments by Geography (%), 2005-2010 128
Figure 78: Atypical Bronchitis Therapeutics Market, Global, Co-Developments by Year, 2005-2010 128
Figure 79: Tonsillitis Therapeutics Market, Global, Revenues ($m), 2001-2009 130
Figure 80: Tonsillitis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 131
Figure 81: Tonsillitis Therapeutics Market, By Region, Revenue Forecasts ($m), 2001-2016 132
Figure 82: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 133
Figure 83: Tonsillitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2016 134
Figure 84: Tonsillitis Therapeutics Market, Global, Prevalence Population (Million), 2001-2016 135
Figure 85: Tonsillitis Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2016 136
Figure 86: Tonsillitis Therapeutics Market, Global, Diagnosed Population (Million), 2001-2016 137
Figure 87: Tonsillitis Therapeutics Market, Global, Prescription Population (Million), 2001-2016 138
Figure 88: Tonsillitis Therapeutics Market, Market Drivers and Barriers, 2009-2016 139
Figure 89: Tonsillitis Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2010 140
Figure 90: Tonsillitis Therapeutics Market, Global, M&A Deals by Deal Type (%), 2004-2010 141
Figure 91: Tonsillitis Therapeutics Market, Global, M&A Deals by Year (%), 2004-2010 141
Figure 92: Sinusitis Therapeutics Market, Global, Revenues ($bn), 2001-2009 144
Figure 93: Sinusitis Therapeutics Market, Global, Revenues Forecasts ($bn), 2009-2016 145
Figure 94: Sinusitis Therapeutics Market, By Region, Revenues Forecasts ($m), 2001-2016 146
Figure 95: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 147
Figure 96: Sinusitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2016 148
Figure 97: Sinusitis Therapeutics Market, Global, Prevalence Population (Million), 2001-2016 149
Figure 98: Sinusitis Therapeutics Market, Global, Treatment Seeking Population (million), 2001-2016 150
Figure 99: Sinusitis Therapeutics Market, Global, Diagnosed Population (Million), 2001-2016 151
Figure 100: Sinusitis Therapeutics Market, Global, Prescription Population (Million), 2001-2016 152
Figure 101: Sinusitis Therapeutics Market, Market Drivers and Barriers, 2009-2016 153
Figure 102: Sinusitis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 154
Figure 103: Sinusitis Therapeutics Market, Global, Strategic Consolidations (%), 2004-2010 156
Figure 104: Sinusitis Therapeutics Market, Global, M&A Deals By Geography (%), 2004-2010 156
Figure 105: Sinusitis Therapeutics Market, Global, M&A Deals By Deal Type (%), 2004-2010 157
Figure 106: Sinusitis Therapeutics Market, Global, M&A Deals By Year, 2004-2010 158
Figure 107: Sinusitis Therapeutics Market, Global, Licensing Agreements By Geography (%), 2004-2010 158
Figure 108: Sinusitis Therapeutics Market, Global, Licensing Agreements By Year (%), 2004-2010 159
Figure 109: Sinusitis Therapeutics Market, Global, Licensing Agreements By Organizations (%), 2004-2010 160
Figure 110: Otitis Media Therapeutics Market, Global, Revenues ($m), 2001-2009 162
Figure 111: Otitis Media Therapeutics Market, Global, Revenues Forecasts ($m), 2009-2016 163
Figure 112: Otitis Media Therapeutics Market, By Region, Revenues Forecasts ($m), 2001-2016 164
Figure 113: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 165
Figure 114: Otitis Media Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2016 166
Figure 115: Otitis Media Therapeutics Market, Global, Prevalence Population (Million), 2001-2016 167
Figure 116: Otitis Media Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2016 168
Figure 117: Otitis Media Therapeutics Market, Global, Diagnosed Population (Million), 2001-2016 169
Figure 118: Otitis Media Therapeutics Market, Global, Prescription Population (Million), 2001-2016 170
Figure 119: Otitis Media Therapeutics Market, Global, Market Drivers and Barriers, 2009-2016 171
Figure 120: Otitis Media Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 172
Figure 121: Otitis Media Therapeutics Market, Global, M&A Deals By Geography (%), 2009-2010 174
Figure 122: Otitis Media Therapeutics Market, Global, M&A Deals By Deal Type (%), 2009-2010 175
Figure 123: Otitis Media Therapeutics Market, Global, M&A Deals By Year, 2009-2010 175
Figure 124: Antibacterial, Pfizer Company Overview, 2010 177
Figure 125: Antibacterial, Pfizer SWOT Profile, 2010 178
Figure 126: Antibacterial, Johnson & Johnson Company Overview, 2010 178
Figure 127: Antibacterial, Johnson & Johnson SWOT Profile, 2010 179
Figure 128: Antibacterial, Daiichi-Sankyo Company Overview, 2010 180
Figure 129: Antibacterial, Daiichi-Sankyo SWOT Profile, 2010 181
Figure 130: Antibacterial, Bayer HealthCare AG, Company Overview, 2010 181
Figure 131: Antibacterial, Bayer HealthCare AG, SWOT Profile, 2010 182
Figure 132: Antibacterial, Sanofi Aventis Company Overview, 2010 183
Figure 133: Antibacterial, Sanofi Aventis SWOT Profile, 2010 184
Figure 134: Antibacterial, Abbott Laboratories Company Overview, 2010 184
Figure 135: Antibacterial, Abbott Laboratories SWOT Profile, 2010 185
Figure 136: Antibacterial, Teva Pharmaceutical Industries Limited Company, 2010 186
Figure 137: GBI Research Market Forecasting Model 193

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *